Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine…

Overview of attention for article published in Diabetes Therapy, March 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 20,059 followers.

Switch to combined #lixisenatide & basal #insulin glargine in poorly controlled #T2D patients with premixed insulin https://t.co/EqHFycibsW

Switch to Combined GLP1 RA Lixisenatide & Basal Glargine Poorly Controlled T2DM Patients on Premixed Insulin https://t.co/pfZU3LurIu

Switch to Combined GLP1 RA Lixisenatide & Basal Glargine Poorly Controlled T2DM Patients on Premixed Insulin https://t.co/JnM2VdboAt

Switch to Combined GLP1 RA Lixisenatide & Basal Glargine Poorly Controlled T2DM Patients on Premixed Insulin https://t.co/caflNBih9d

Switch to Combined GLP1 RA Lixisenatide & Basal Glargine Poorly Controlled T2DM Patients on Premixed Insulin https://t.co/KbeyeuGEFe

Switch to Combined GLP1 RA Lixisenatide & Basal Glargine Poorly Controlled T2DM Patients on Premixed Insulin https://t.co/40C1RkYiIR